Paper Details

  1. Home
  2. Paper Details

Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).

Author: JohnsonK P

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This multicenter, placebo-controlled trial evaluated the efficacy of copolymer I (Copazone) in treating relapsing-remitting multiple sclerosis (MS). The copolymer I group had 32% fewer relapses and significantly more patients remained relapse-free compared to the placebo group. Copolymer I is being considered for approval as a commercially available treatment for MS.
Paper Details　
Original Abstract of the Article :
Copolymer I (Copazone) was evaluated in a multicenter, placebo-controlled, double-blind trial at 11 universities. Two hundred and fifty-one relapsing-remitting ambulatory MS patients were randomized to receive 20 mg of copolymer I or placebo by daily subcutaneous injection for approximately 30 month...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/135245859600100606

データ提供：米国国立医学図書館（NLM）

Copolymer I: A New Hope for Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting multiple sclerosis (RRMS) is a chronic neurological disorder characterized by periods of relapse and remission. This study evaluated the efficacy and safety of copolymer I (Copaxone) in treating RRMS. The study involved 251 patients with RRMS who were randomly assigned to receive either copolymer I or placebo. The results showed that copolymer I significantly reduced the frequency of relapses and improved neurological function in patients with RRMS. The study concluded that copolymer I is an effective and safe treatment for RRMS and is being considered for approval as a commercially available agent for the control of multiple sclerosis.

Copolymer I: A New Hope for Relapsing-Remitting Multiple Sclerosis

This study provides encouraging evidence for the efficacy and safety of copolymer I in treating RRMS. The researchers found that copolymer I significantly reduced the frequency of relapses and improved neurological function in patients with RRMS. This research offers a glimmer of hope for individuals living with RRMS.

A New Oasis in the Desert of Multiple Sclerosis Treatment

This study offers a beacon of hope for patients with RRMS. The findings suggest that copolymer I is an effective and safe treatment option. It's like finding a new oasis in the vast desert of multiple sclerosis treatment, offering a refreshing respite for patients struggling with this debilitating condition.

Dr. Camel's Conclusion

This study provides evidence for the effectiveness and safety of copolymer I in treating RRMS. It's like finding a hidden oasis in the vast desert of multiple sclerosis research. This research offers hope for individuals living with RRMS and underscores the importance of continued research in finding effective treatments for this debilitating condition.

Date :
  1. Date Completed 1997-12-12
  2. Date Revised 2017-02-14
Further Info :

Pubmed ID

9345409

DOI: Digital Object Identifier

10.1177/135245859600100606

Related Literature

Article Analysis
・Side Effects of glatiramer injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.